GC Biopharma Corp.
Research GC Biopharma Corp. (006280.KS) on Bullrun: market cap KRW 1.46T, dividend yield 1.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker006280.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 1.46T
- Dividend yield1.1%
- Financial periodQ2 2026
- RevenueKRW 421.18B
- Net incomeKRW 1.98B
- Free cash flowKRW 1.19B
- Gross margin26.0%
Valuation Snapshot
latest market cap is KRW 1.46T; dividend yield is 1.1%.
Peer valuation comparison
Latest dividend yield is 1.09% versus a Healthcare sector median of 2.4% (54.6% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 1.46T | n/a | 1.2% | 1500 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1500 KRW, yield 1.1%.
About GC Biopharma Corp.
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief.
ETFs that hold GC Biopharma Corp.
US-listed ETFs
GC Biopharma Corp. is held by 25 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | <0.01% | 0.09% |
| Vanguard FTSE Developed Markets Index Fund ETF Shares (VEA) | <0.01% | 0.03% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Schwab International Equity ETF (SCHF) | <0.01% | 0.03% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| iShares Core MSCI Total International Stock ETF (IXUS) | <0.01% | 0.07% |
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GC Biopharma Corp.'s market cap?
GC Biopharma Corp.'s market capitalization is KRW 1.46T.
Does GC Biopharma Corp. pay a dividend?
GC Biopharma Corp. has a dividend yield of 1.1%.
What does GC Biopharma Corp. do?
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj.